Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04587817
Other study ID # 20200915
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date October 15, 2020
Est. completion date December 1, 2023

Study information

Verified date October 2020
Source Peking University First Hospital
Contact Yun Bai, MD
Phone (+86)010 83575641
Email 08043@pkufh.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This trial will explore effectiveness and safety using the combination therapy of camrelizumab and hyperfractionated radiotherapy in patients with massive tumor including non-small cell lung cancer, soft tissue sarcoma or urothelial carcinoma. Hypofractionation which represented by stereotactic body radiation therapy (SBRT) is a technique that delivers higher daily doses of radiation over a shorter period of time. This trial will also observe the index which can influencing the curative effect of hyperfractionated radiotherapy combined with immunotherapy.


Description:

This trial is a prospective, observational, single-center, single-arm clinical research. This trial will explore effectiveness and safety using the combination therapy of camrelizumab and hyperfractionated radiotherapy in patients with massive tumor including non-small cell lung cancer, soft tissue sarcoma or urothelial carcinoma. All enrolled patients will receive the following treatments: camrelizumab 200mg every 2 weeks until disease progression (as determined by RECIST 1.1), intolerance, or patient/physician decision to stop treatment. One week following completion of the first immunotherapy, hypofractionated radiotherapy(SABR) with tumor center dose of 24-32Gy/8Gy/3-4f and surrounding important organs at risk ≤3.0Gy will be performed. And the routine radiotherapy will be started with reaching a radical cure dose for the tumor margin. Generally, the radiotherapy will end before the fourth immunotherapy.

During treatment participants will be assessed for curative effects and the occurrence of adverse events. Following treatment, participants will be assessed at a clinic visit every 3 months to collect survival information and follow-up treatment information. The planned sample size is 60 study participants.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 60
Est. completion date December 1, 2023
Est. primary completion date September 19, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Age =18 years old, male or female;

2. ECOG score will be 0 - 2;

3. The life expectancy will be longer than 12 weeks;

4. Patients with non-small cell lung cancer, soft tissue sarcoma or urothelial carcinoma were confirmed by histopathology;

5. Contain at least 1 measurable lesion with the largest long diameter = 5cm;

6. The main organ functions are normal, and the results of laboratory test must be met the following criteria: Absolute neutrophil count(ANC): more than 1.5 × 109/L; Platelets(PLT): more than 75× 109/L; Total Bilirubin(TBil):less than the upper normal limit (ULN); ALT and AST:less than 2.5 folds of the upper normal limit (ULN),if there is liver metastasis, ALT and AST must be less than 5 folds of the upper normal limit (ULN) ; Urea Nitrogen (BUN): less than 2.5×ULN;Endogenous creatinine clearance =45 ml/min (Cockcroft-Gault formula);

7. Female subjects of childbearing age must undergo a serum pregnancy test within 3 days before starting the study drug, and the result is negative.Female and male subjects should take effective contraceptive measures from the beginning of treatment to within 3 months after the end of treatment;

8. Agreeing to participate in this study and signing a written informed consent.

Exclusion Criteria:

1. Central nervous system metastasis (including brain metastasis, meningeal metastasis, etc.);

2. Other immunosuppressive drugs used within 14 days before before study drug administration, excluding nasal sprays and inhaled corticosteroids or physiological doses of systemic steroids (ie not more than 10 mg/day of prednisolone or Other corticosteroids of equivalent pharmacological physiological dose);

3. Hypertension and unable to be controlled within normal level following treatment of anti-hypertension agents: systolic blood pressure =140 mmHg, diastolic blood pressure = 90 mmHg;

4. Clinically significant cardiovascular diseases:Myocardial ischemia or myocardial infarction above grade II, ventricular arrhythmia which poorly controlled,QTc>450ms(male)/QTc>470ms (female);Congestive heart failure (New York heart association (NYHA) class is ?~?);or cardiac color Doppler ultrasound examination revealed that the left ventricular ejection fraction (LVEF) <50%;

5. Accompanied by uncontrolled pleural effusion, pericardial effusion, or ascites that requires repeated drainage;

6. Patients with any active autoimmune disease or history of autoimmune disease, including but not limited to the following: hepatitis, pneumonitis, uveitis, colitis (inflammatory bowel disease), hypophysitis, vasculitis, nephritis, hyperthyroidism, and hypothyroidism;

7. Asthma that requires intermittent use of bronchodilators or other medical intervention should be excluded(Asthma has been completely relieved in childhood, and those without any intervention after adulthood can be included);

8. Coagulation abnormalities (INR>1.5?PT>ULN+4s?APTT >1.5 ULN), with bleeding tendency or are receiving thrombolytic or anticoagulant therapy;

9. Proteinuria = (++) and 24 hours total urine protein > 1.0 g;

10. Received major surgery or suffered severe traumatic injury, fracture or ulcer within 4 weeks before enrollment;

11. Severe infections (such as intravenous infusion of antibiotics, antifungal or antiviral drugs) within 4 weeks before the first administration, or unexplained fever> 38.5°C during the screening period/before the first administration;

12. Clinically significant hemoptysis or more than half a teaspoon (2.5ml) of hemoptysis per day occurred within 2 months before enrollment; or Clinically significant bleeding symptoms or tendency, such as gastrointestinal bleeding, hemorrhagic Gastric ulcer, fecal occult blood=++ at baseline, or vasculitis, etc.;

13. Arterial/venous thrombosis events occurred in the 12 months before enrollment, such as cerebrovascular accidents (including temporary ischemic attacks, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism;

14. History of immunodeficiency or human immunodeficiency virus (HIV) infection, HBV DNA>500 IU/ml, HCV RNA>1000copies/ml, HBsAg+ and anti-HCV+;

15. Patients with a clear history of allergies may be potentially allergic or intolerant to camrelizumab and apatinib;

16. Patients who have a history of psychotropic drug abuse and cannot be quit or have mental disorders;

17. Other condition, illness, psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or stereotactic radiotherapy administration, or may interfere with the interpretation of study results and in the judgment of the investigator would make the patient inappropriate for entry into this study.

Study Design


Related Conditions & MeSH terms


Intervention

Combination Product:
camrelizumab+hyperfractionated radiotherapy
Immunotherapy combined with hyperfractionated radiotherapy

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Peking University First Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary Progression free survival (PFS) The date of first treatment until the date of progression using the RECIST 1.1 criteria, or death due to any cause, whichever comes first. 2 years
Secondary Subject safety Number of Adverse Events using NCI CTCAE 5.0 2 years
Secondary Overall Survival(OS) Overall survival, defined from the date of first treatment to the date of death due to any cause. 2 years
Secondary Objective response rate(ORR) Objective response rate, which is defined as the proportion of subjects who achieve a best response of complete response (CR) or partial response (PR) using the RECIST 1.1 criteria. 2 years
Secondary Disease control rate(DCR) Disease control rate, which is defined as the proportion of subjects who achieve a response of complete response,partial response and stable disease (PR+CR+SD) in the total number of evaluable subjects using the RECIST 1.1 criteria 2 years
Secondary Local Control Rate Local Control Rate, which is defined as the proportion of subjects who achieve a response of remission and stable disease (PR+CR+SD) evaluated by RECIST 1.1 after radiotherapy 2 years
Secondary Distant metastasis-free survival(DMFS) Distant metastasis-free survival(DMFS), defined from the date of first treatment to the date of the appearance of distant metastasis or death due to any cause. 2 years
Secondary Response rate of lesions that did not receive radiotherapy Response rate of lesions that did not receive radiotherapy, which is defined as the percentage of the number of cases with tumors that have not received radiotherapy in remission and stable disease (PR+CR+SD) in the total number of evaluable cases using the RECIST 1.1 criteria. 2 years
Secondary Quality of Life: EORTC QLQ-C30 questionnaire Quality of life, which will be evaluated using the EORTC(The European Organization for Reasearch and Treatment of Cancer) QLQ-C30(Quality of Life Questionnare-Core 30) questionnaire. The questionnaire contains 30 items. Items 29 and 30 are divided into seven levels, which are counted from 1 to 7 points, 1 is very poor, and 7 is very good. Other items are divided into 4 levels: no at all, a little bit, a lot, and very, and they are directly rated from 1 to 4 points 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT05848011 - A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer Phase 2
Recruiting NCT05161572 - Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer Phase 2
Recruiting NCT06165900 - Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC Phase 2
Recruiting NCT06120127 - Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence Phase 2
Recruiting NCT06262581 - Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery Phase 2
Recruiting NCT05176002 - Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma. Phase 1/Phase 2
Not yet recruiting NCT05909137 - Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer
Recruiting NCT04500990 - MRI DWI None-Gaussian Model Predicting Early Response to Immunotherapy in Digestive System Malignancies: a Prospective Observational Study
Not yet recruiting NCT04372732 - Serum Autoantibodies in Predicting the Efficacy of Anti-PD-1 Treatment in Patients With Advanced NSCLC
Completed NCT02692976 - Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients Phase 2
Completed NCT03763630 - MAPS & ITEC Cohorts: 6-8 Years Follow-up Phase 2
Not yet recruiting NCT06012318 - Dynamic Follow-up of Symptoms Based on Patient-reported Outcomes in Immunotherapy for Esophageal Cancer: a Prospective Multicentre Cohort Study (SPRING)
Not yet recruiting NCT05479240 - Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer Phase 2
Recruiting NCT05515796 - Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors Phase 2
Recruiting NCT04711330 - Response and Toxicity Prediction by Microbiome Analysis After Concurrent Chemoradiotherapy
Recruiting NCT03701607 - Effect of Chemotherapy on PD-L1 in NSCLC
Recruiting NCT03683407 - Effect of Chemotherapy on TMB in NSCLC
Completed NCT03357861 - Cancer Patients Treated With Immunotherapy in Intensive Care Unit
Recruiting NCT05223088 - Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer Phase 2
Completed NCT05657262 - Effect of Z Technıque on Pain, Comfort, Symptoms in Ummunotherapy Areas N/A